Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug (Q36399718)

14 August 2017

1 reference

title

Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug (English)

1 reference

14 August 2017

1 reference

Mary Beth Wire

1

1 reference

14 August 2017

Mark J Shelton

series ordinal

2

1 reference

14 August 2017

Scott Studenberg

series ordinal

3

1 reference

14 August 2017

1 January 2006

1 reference

Clinical Pharmacokinetics

14 August 2017

1 reference

14 August 2017

45

1 reference

14 August 2017

2

1 reference

14 August 2017

137-168

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200645020-00002

14 August 2017

0 references

cites work

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200645020-00002

Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects

21 January 2018

1 reference

12 December 2020

The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution

1 reference

12 December 2020

Effervescent and standard formulations of ranitidine--a comparison of their pharmacokinetics and pharmacology.

1 reference

12 December 2020

Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.

1 reference

12 December 2020

Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.

1 reference

12 December 2020

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus

1 reference

12 December 2020

Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers

1 reference

12 December 2020

Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

1 reference

12 December 2020

Cyp3A regulation: from pharmacology to nuclear receptors.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

12 December 2020

Statistical issues in a modeling approach to assessing bioequivalence or PK similarity with presence of sparsely sampled subjects

1 reference

12 December 2020

Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.

1 reference

12 December 2020

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin

1 reference

12 December 2020

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients

1 reference

12 December 2020

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

12 December 2020

The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir

1 reference

12 December 2020

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

12 December 2020

Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes

1 reference

12 December 2020

Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

1 reference

12 December 2020

Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

1 reference

12 December 2020

Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein

1 reference

12 December 2020

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

1 reference

12 December 2020

Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity

1 reference

12 December 2020

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function

1 reference

12 December 2020

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers

1 reference

12 December 2020

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus

1 reference

12 December 2020

The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).

1 reference

12 December 2020

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line

1 reference

12 December 2020

The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).

1 reference

12 December 2020

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

1 reference

12 December 2020

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

1 reference

12 December 2020

Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir

1 reference

12 December 2020

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1 reference

12 December 2020

The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion

1 reference

12 December 2020

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

1 reference

12 December 2020

Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir

1 reference

12 December 2020

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results

1 reference

12 December 2020

HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

1 reference

12 December 2020

Pharmacokinetic interaction between ritonavir and clarithromycin

1 reference

12 December 2020

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients

1 reference

12 December 2020

Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors

1 reference

12 December 2020

Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir

1 reference

12 December 2020

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir

1 reference

12 December 2020

Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.

1 reference

12 December 2020

Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects

1 reference

12 December 2020

A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.

1 reference

12 December 2020

Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects

1 reference

12 December 2020

Use of the nuclear receptor PXR to predict drug interactions

1 reference

12 December 2020

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

1 reference

12 December 2020

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients

1 reference

12 December 2020

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

1 reference

12 December 2020

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes

1 reference

12 December 2020

Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects

1 reference

12 December 2020

10.2165/00003088-200645020-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

0 references

1 reference